Pilot randomized trial of 14-day versus 28-day inhaled tobramycin cycles in non-cystic fibrosis bronchiectasis with chronic Pseudomonas infection

Phase 4, randomised trial of tobramycin in bronchiectasis and Pseudomonal infection (2 arms), sponsored by Vall d'Hebron University Hospital. Primary endpoints: Clinical efficacy of inhaled tobramycin and Clinical efficacy of 14-day versus 28-day treatment cycles. Started Nov 2008; status: active.